Jason S McLellan
Overview
Explore the profile of Jason S McLellan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
203
Citations
20972
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wasdin P, Johnson N, Janke A, Held S, Marinov T, Jordaan G, et al.
bioRxiv
. 2025 Mar;
PMID: 40027781
The traditional process of antibody discovery is limited by inefficiency, high costs, and low success rates. Recent approaches employing artificial intelligence (AI) have been developed to optimize existing antibodies and...
2.
Antibodies targeting Crimean-Congo hemorrhagic fever virus GP38 limit vascular leak and viral spread
Pahmeier F, Monticelli S, Feng X, Hjorth C, Wang A, Kuehne A, et al.
Sci Transl Med
. 2025 Feb;
17(786):eadq5928.
PMID: 39970234
Crimean-Congo hemorrhagic fever virus (CCHFV) is a priority pathogen transmitted by tick bites, with no vaccines or specific therapeutics approved to date. Severe disease manifestations include hemorrhage, endothelial dysfunction, and...
3.
Abiona O, Wang N, Leist S, Schafer A, Cockrell A, Wang L, et al.
iScience
. 2025 Feb;
28(2):111632.
PMID: 39898019
The COVID-19 pandemic underscores the need to prepare for future emerging coronavriuses (CoVs) by understanding the principles behind effective CoV vaccine design such as protective immunity and antibody responses. To...
4.
McFadden E, Monticelli S, Wang A, Ramamohan A, Batchelor T, Kuehne A, et al.
Cell
. 2024 Dec;
188(2):303-315.e13.
PMID: 39701101
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tickborne virus that can cause severe disease in humans with case fatality rates of 10%-40%. Although structures of CCHFV glycoproteins GP38 and Gc...
5.
Abu-Shmais A, Guo L, Khalil A, Miller R, Janke A, Vukovich M, et al.
bioRxiv
. 2024 Nov;
PMID: 39554078
Human respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) are frequent drivers of morbidity and mortality in susceptible populations, most often infantile, older adults, and immunocompromised. The primary target of...
6.
Tse A, Acreman C, Ricardo-Lax I, Berrigan J, Lasso G, Balogun T, et al.
PLoS Pathog
. 2024 Nov;
20(11):e1012704.
PMID: 39546542
Understanding the zoonotic risks posed by bat coronaviruses (CoVs) is critical for pandemic preparedness. Herein, we generated recombinant vesicular stomatitis viruses (rVSVs) bearing spikes from divergent bat CoVs to investigate...
7.
Goldsmith J, Nguyen A, Wilen R, Wijagkanalan W, McLellan J, Maynard J
bioRxiv
. 2024 Oct;
PMID: 39386618
Pertussis toxin (PT) is a key protective antigen in vaccine- and natural immunity-mediated protection from infection. Despite its importance, no PT-neutralizing epitopes have been characterized structurally. To define neutralizing epitopes...
8.
Johnson N, Wall S, Kramer K, Holt C, Periasamy S, Richardson S, et al.
Structure
. 2024 Sep;
32(11):1893-1909.e11.
PMID: 39326419
The continued emergence of deadly human coronaviruses from animal reservoirs highlights the need for pan-coronavirus interventions for effective pandemic preparedness. Here, using linking B cell receptor to antigen specificity through...
9.
Abu-Shmais A, Vukovich M, Wasdin P, Suresh Y, Marinov T, Rush S, et al.
mBio
. 2024 Sep;
15(10):e0156024.
PMID: 39264172
Throughout life, humans experience repeated exposure to viral antigens through infection and vaccination, resulting in the generation of diverse, antigen-specific antibody repertoires. A paramount feature of antibodies that enables their...
10.
Sponholtz M, Byrne P, Lee A, Ramamohan A, Goldsmith J, McCool R, et al.
Proc Natl Acad Sci U S A
. 2024 Sep;
121(37):e2404250121.
PMID: 39231203
Human cytomegalovirus (HCMV) glycoprotein B (gB) is a class III membrane fusion protein required for viral entry. HCMV vaccine candidates containing gB have demonstrated moderate clinical efficacy, but no HCMV...